ABEONA THERAPEUTICS INC. Selling, General and Administrative Expense
ABEONA THERAPEUTICS INC. (ABEO) reported Selling, General and Administrative Expense of $15.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $15.84M, a 7.66% decline year-over-year.
- ABEONA THERAPEUTICS INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $19.50M, a 99.28% increase year-over-year.
- ABEONA THERAPEUTICS INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $18.78M, a 144.62% increase year-over-year.
- ABEONA THERAPEUTICS INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $19.31M, a 201.59% increase year-over-year.
- ABEONA THERAPEUTICS INC. selling, general and administrative expense for fiscal 2025 was $65.03M, a 117.85% increase from fiscal 2024.
- ABEONA THERAPEUTICS INC. selling, general and administrative expense for fiscal 2024 was $29.85M.
- ABEONA THERAPEUTICS INC. selling, general and administrative expense for fiscal 2014 was $3.71M, a 23.21% decline from fiscal 2013.
- ABEONA THERAPEUTICS INC. selling, general and administrative expense for fiscal 2013 was $4.83M, a 19.75% decline from fiscal 2012.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.84M 10-Q · filed 2026-08-13 | $35.34M 10-Q · filed 2026-08-13 | $54.12M derived: sum of 3 quarters · filed 2026-08-13 | $73.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $19.50M 10-Q · filed 2026-05-13 | $38.28M derived: sum of 2 quarters · filed 2026-05-13 | $57.60M derived: sum of 3 quarters · filed 2026-05-13 | $74.75M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $18.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $38.10M derived: sum of 2 quarters · filed 2026-03-17 | $55.24M derived: sum of 3 quarters · filed 2026-08-13 | $65.03M 10-K · filed 2026-03-17 |
| 2025-09-30 | $19.31M 10-Q · filed 2025-11-12 | $36.46M derived: sum of 2 quarters · filed 2026-08-13 | $46.25M 10-Q · filed 2025-11-12 | $53.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $17.15M 10-Q · filed 2026-08-13 | $26.93M 10-Q · filed 2026-08-13 | $34.61M derived: sum of 3 quarters · filed 2026-08-13 | $41.02M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $9.79M 10-Q · filed 2026-05-13 | $17.46M derived: sum of 2 quarters · filed 2026-05-13 | $23.87M derived: sum of 3 quarters · filed 2026-05-13 | $32.51M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $7.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $14.08M derived: sum of 2 quarters · filed 2026-03-17 | $22.73M derived: sum of 3 quarters · filed 2026-03-17 | $29.85M 10-K · filed 2026-03-17 |
| 2024-09-30 | $6.40M 10-Q · filed 2025-11-12 | $15.05M derived: sum of 2 quarters · filed 2025-11-12 | $22.17M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $8.65M 10-Q · filed 2025-08-14 | $15.77M 10-Q · filed 2025-08-14 | ||
| 2014-12-31 | $657.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $1.45M derived: sum of 2 quarters · filed 2015-03-31 | $2.32M derived: sum of 3 quarters · filed 2015-03-31 | $3.71M 10-K · filed 2015-03-31 |
| 2014-09-30 | $795.00K 10-Q · filed 2014-11-14 | $1.66M derived: sum of 2 quarters · filed 2014-11-14 | $3.06M 10-Q · filed 2014-11-14 | $3.11M derived: sum of 4 quarters · filed 2015-03-31 |
| 2014-06-30 | $868.00K 10-Q · filed 2014-08-14 | $2.26M 10-Q · filed 2014-08-14 | $2.32M derived: sum of 3 quarters · filed 2015-03-31 | $2.96M derived: sum of 4 quarters · filed 2015-03-31 |
| 2014-03-31 | $733.00K 10-Q · filed 2014-05-12 | $1.45M derived: sum of 2 quarters · filed 2015-03-31 | $2.09M derived: sum of 3 quarters · filed 2015-03-31 | $4.23M derived: sum of 4 quarters · filed 2015-03-31 |
| 2013-12-31 | $717.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $1.36M derived: sum of 2 quarters · filed 2015-03-31 | $3.50M derived: sum of 3 quarters · filed 2015-03-31 | $4.83M 10-K · filed 2015-03-31 |
| 2013-09-30 | $642.00K 10-Q · filed 2014-11-14 | $2.78M derived: sum of 2 quarters · filed 2014-11-14 | $4.12M 10-Q · filed 2014-11-14 | $5.65M derived: sum of 4 quarters · filed 2014-11-14 |
| 2013-06-30 | $2.14M 10-Q · filed 2014-08-14 | $3.48M 10-Q · filed 2014-08-14 | $5.01M derived: sum of 3 quarters · filed 2014-08-14 | $6.43M derived: sum of 4 quarters · filed 2014-08-14 |
| 2013-03-31 | $1.34M 10-Q · filed 2014-05-12 | $2.87M derived: sum of 2 quarters · filed 2014-05-12 | $4.29M derived: sum of 3 quarters · filed 2014-05-12 | $5.70M derived: sum of 4 quarters · filed 2014-05-12 |
| 2012-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-26 | $2.96M derived: sum of 2 quarters · filed 2014-03-26 | $4.36M derived: sum of 3 quarters · filed 2014-03-26 | $6.02M 10-K · filed 2014-03-26 |
| 2012-09-30 | $1.42M 10-Q · filed 2013-11-14 | $2.83M derived: sum of 2 quarters · filed 2013-11-14 | $4.49M 10-Q · filed 2013-11-14 | |
| 2012-06-30 | $1.41M 10-Q · filed 2013-08-14 | $3.07M 10-Q · filed 2013-08-14 | ||
| 2012-03-31 | $1.66M 10-Q · filed 2013-05-15 | |||
| 2011-12-31 | $5.75M 10-K · filed 2013-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |